Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
- NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato's drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.
- 10/24/2024
|
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
- Dallas, Texas--(Newsfile Corp. - October 2, 2024) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners initiates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Advancing proprietary, synthetic first and best-in-class cannabinoid and psychedelic-assisted therapeutics Conducting FDA phase 2/3 trial, IHL-42X, for the treatment of Obstructive Sleep Apnea (OSA) IHL-42X pivotal phase 2 top-line data expected first half 2025 Click image above to view full announcement.
- 10/02/2024
|
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
- NEW YORK and MELBOURNE, Australia, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious chronic diseases and significant unmet medical needs, today reported fiscal full year financial results and provided business updates.
- 09/30/2024
|
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
- A new survey conducted by Quantum Research Group, LLC finds that more than half of patients diagnosed with sleep apnea are not satisfied with their current treatment. Nearly 70 percent of patients express a willingness to switch to a prescribed pill-form treatment.
- 09/09/2024
|
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
- NEW YORK and MELBOURNE, Australia, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies is pleased to announce that it has received approval from the US Food and Drug Administration (‘FDA') to conduct the Company's Investigational New Drug (‘IND') opening Phase 2 clinical trial. The trial will investigate Incannex's psilocybin pharmaceutical formulation, known as PSX-001, in conjunction with psychotherapy in patients with generalised anxiety disorder in the United States and the United Kingdom.
- 08/05/2024
|
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
- NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is pleased to announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial.
- 07/30/2024
|
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
- NEW YORK and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that patient dosing has commenced in the Company's Phase 2/3 clinical trial to assess safety and efficacy of IHL-42X in patients with obstructive sleep apnea (‘OSA').
- 05/30/2024
|
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
- MELBOURNE, Australia and NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for treatment of Opioid Use Disorder (OUD).
- 05/07/2024
|
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
- Dallas, Texas--(Newsfile Corp. - May 1, 2024) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Potentially Transformative therapies for Generalized Anxiety Disorder (GAD)." This report explores the pervasive issue of GAD, a condition affecting millions worldwide, and potentially transformative therapies which will change the landscape of future treatments.
- 05/01/2024
|
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
- MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse.
- 02/16/2024
|
Clarion Clinics Open for Psychedelic-Assisted Treatments
- Highlights: Clarion's Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy. Clarion Clinics' built-for-purpose clinic in Melbourne is now open for treatment, and will begin screening patients immediately.
- 02/01/2024
|
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
- MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to announce that patient dosing has commenced in the Phase 2 clinical trial assessing IHL-675A in patients with rheumatoid arthritis (RA).
- 01/24/2024
|
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
- Highlights: 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia. Topline results from the trial anticipated within current Q1 2024.
- 01/18/2024
|
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
- MELBOURNE, Australia and NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies is pleased to announce that an independent Institutional Review Board (IRB) has approved the protocol for the Company's Phase 2/3 clinical trial to be conducted in the United States to assess safety and efficacy of proprietary combination drug candidate IHL-42X in patients with obstructive sleep apnea (OSA). IRB approval of the protocol is a key step in activation of clinical trial sites for the RePOSA study.
- 01/17/2024
|
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
- Highlights: Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD. HREC approval is required for the administration of psychedelic drugs in Australia.
- 12/21/2023
|
5 Biotech stocks tapping into unmet mental health treatment needs
- Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giving patients new hope for recovery and the ability to thrive.
- 12/20/2023
|
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
- MELBOURNE, Australia and NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex' or the ‘Company'), a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to provide the following update on its proprietary IHL-42X drug candidate.
- 12/06/2023
|
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
- Korro Bio is working on an RNA-editing platform, and its stock price shot up 171% in November. Gyre Therapeutics is a commercial-stage drugmaker in China that could expand into the lucrative U.S. market.
- 12/02/2023
|
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
- MELBOURNE, Australia and NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex Healthcare from Australia to the United States has been implemented as of yesterday, November 28, 2023 New York time (November 29, 2023 Melbourne time).
- 11/29/2023
|
Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC
- MELBOURNE, Australia, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) (the “Company” or “Incannex”) is pleased to announce that the Federal Court of Australia (“Court”) has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States (“Scheme”), under which Incannex Healthcare Inc. (“Holdco”) will become the ultimate parent company of Incannex Healthcare Limited following the implementation of the Scheme.
- 11/16/2023
|
Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023
- MELBOURNE, Australia, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing cannabinoid pharmaceutical medicines and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023. Incannex will be presenting and taking one on one meetings virtually. Mr Joel Latham, CEO and Managing Director of Incannex, will provide an overview of the Company's business during the presentation.
- 09/08/2023
|
Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
- MELBOURNE, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that its subsidiary Psychennex Pty Ltd has commenced preparations of an investigational new drug (‘IND') application to the U.S. Food and Drug Administration (‘FDA') for the Company's psilocybin assisted psychotherapy development program (‘Psi-GAD').
- 08/24/2023
|
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
- MELBOURNE, Australia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs, is pleased to announce that it has received approval from the US Food and Drug Administration (‘FDA') to conduct the Company's Investigational New Drug (‘IND') opening pivotal IHL-42X Phase 2/3 clinical trial in the United States as planned.
- 08/22/2023
|
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
- Highlights: Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3 opening. First clinic in Abbotsford, Melbourne, nearing fit-out completion.
- 08/08/2023
|
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
- MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex' or the ‘Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2023. Incannex is undertaking a multitude of U.S. Food and Drug Administration (‘FDA') research and development (‘R&D') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals.
- 07/28/2023
|
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
- MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed a constructive pre-Investigational New Drug Application (‘pre-IND') meeting with the U.S. Food and Drug Administration (‘FDA') for its proprietary drug product IHL-675A for treatment of rheumatoid arthritis (‘RA').
- 07/26/2023
|
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
- MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has successfully submitted an Investigational New Drug (‘IND') application to the US Food and Drug Administration (‘FDA') for IHL-42X for treatment of obstructive sleep apnoea.
- 07/21/2023
|
Top Penny Stocks To Buy? 3 To Watch Before Next Week
- With the uptick of volatility in the stock market today, there's no question as to why penny stocks are red hot. Whether the broader markets are risk-on or risk-off, the stock market is crashing or rallying, or if there's a significant global catalyst, cheap stocks are usually a topic of discussion.
- 07/06/2023
|
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
- MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference. The conference is being held virtually on September 26, 2023.
- 06/23/2023
|
Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference
- MELBOURNE, Australia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex' or the ‘Company') a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.
- 09/08/2022
|
5 Cannabis Stocks You Don't Want to Hit 'Snooze' On
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
- 07/22/2022
|
Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference
- MELBOURNE, Australia , June 27, 2022 /PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University and Chief Principal Investigator for Incannex's psilocybin-assisted psychotherapy, will present an overview of progress achieved in Incannex's psychedelic medicine program at the H.C. Wainwright First Annual Mental Health Conference, taking place June 27, 2022.
- 06/27/2022
|
What Happened With These 11 Cannabis Stocks This Week?
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
- 05/20/2022
|
Incannex Healthcare rallies after airing plan to buy cannabis medicine company APIRx
- Incannex Healthcare Ltd. IXHL, -4.23% shares jumped 7% after the Australia-based cannabinoid and psychedelic compound medicine development company said it would pay $93.3 million to acquire APIRx Pharmaceutical USA LLC, a pharmaceutical medicinal cannabinoid product development company.
- 03/24/2022
|
Why Incannex Healthcare Stock Crashed Today
- Profit-taking after a big gain earlier this week took its toll.
- 03/16/2022
|
IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too
- Here's what investors intrigued by today's 100% rise in Incannex Healthcare and IXHL stock may want to know about this company. The post IXHL Stock Alert: 7 Things to Know as Incannex Healthcare Skyrockets Too appeared first on InvestorPlace.
- 03/15/2022
|
What's Going On With Incannex Healthcare's Stock Today?
- Incannex Healthcare Ltd (NASDAQ: IXHL) is soaring Tuesday on abnormally-high volume. The stock has been extremely volatile since the company released a preliminary analysis of data from its phase 2 clinical trial investigating its novel cannabinoid combination product, IHL-42X, for the.
- 03/15/2022
|
The 7 Hottest Cannabis Stocks To Watch This Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.
- 03/14/2022
|
Cannabis Sector Kicks Off March With a Blast of Q4 Earnings
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.
- 03/07/2022
|
